The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats

British Journal of Pharmacology

Volumn 144, Issue 3, 2005, Pages 308-316

  Pickavance, Lucy C ^a   Brand, Christian L ^b   Wassermann, Karsten ^c   Wilding, John P H ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c NOVO NORDISK INC   (United States)

Author keywords

Dietary obesity; Hyperglycaemic clamp; Insulin resistance; Insulin secretion; Pioglitazone; PPAR agonist; Ragaglitazar; Zucker diabetic fatty rat

Indexed keywords

BEZAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; RAGAGLITAZAR; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CELL SURFACE RECEPTOR; INSULIN; LEPTIN RECEPTOR; OXAZINE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLPROPIONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE INFUSION; HYPERGLYCEMIA; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; ADIPOSE TISSUE; ANIMAL; BLOOD; BODY COMPOSITION; BODY WEIGHT; DIET; DRUG EFFECT; DRUG POTENTIATION; ENERGY METABOLISM; GENETICS; GLUCOSE CLAMP TECHNIQUE; METABOLISM; ORGAN SIZE; PANCREAS; PHYSIOLOGY; RAT STRAIN;

ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BODY COMPOSITION; BODY WEIGHT; DIABETES MELLITUS; DIET; ENERGY METABOLISM; GLUCOSE CLAMP TECHNIQUE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; OBESITY; ORGAN SIZE; OXAZINES; PANCREAS; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA; RATS; RATS, INBRED STRAINS; RECEPTORS, CELL SURFACE; THIAZOLIDINEDIONES;

EID: 14644427833     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706041     Document Type: Article

References (41)

1. ARAKAWA, K., ISHIHARA, T., AOTO, M., INAMASU, M., SAITO, A. & IKEZAWA, K. (1998). Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br. J. Pharmacol., 125, 429-436.
2. BRAISSANT, O., FOUFELLE, F., SCOTTO, C., DAUCA, M. & WAHLI, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 137, 354-366.
3. BRAND, C.L., STURIS, J., GOTFREDSEN, C.F., FLECKNER, J., FLEDELIUS, C., HANSEN, B.F., ANDERSEN, B., YE, J.-M., SAUERBERG, P. & WASSERMAN, K. (2003). Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am. J. Physiol., 284, E841-E854.
4. CABRERO, A., LLAVERIAS, G., ROGLANS, N., ALEGRET, M., SANCHEZ, R., ADZET, T., LAGUNA, J.C. & VASQUEZ, M. (1999). Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats. Biochem. Biophys. Res. Commun., 260, 547-556.
5. CHAKRABARTI, R., VIKRAMADITHYAN, R.K., MISRA, P., HIRIYAN, J., RAICHUR, S., DAMARLA, R.K., GERSHOME, C., SURESH, J. & RAJAGOPALAN, R. (2003). Ragaglitazar: a novel PPARα & PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br. J. Pharmacol., 140, 527-537.
6. ETGEN, G.J., OLDHAM, B.A., JOHNSON, W.T., BRODERICK, C.L., MONTROSE, C.R., BROZINICK, J.T., MISENER, E.A., BEAN, J.S., BENSCH, W.R., BROOKS, D.A., SHUKER, A.J., RITO, C.J., MCCARTHY, J.R., ARDECKY, R.J., TYHONAS, J.S., DANA, S.L., BILAKOVICS, J.M., PATERNITI JR, J.R., OGILVIE, K.M., LIU, S. & KAUFFMAN, R.F. (2002). A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes, 51, 1083-1087.
7. FAJAS, L., AUBOEUF, D., RASPÉ, E., SCHOONJANS, K., LEFEBVRE, A.M., SALADIN, R., NAJIB, J., LAVILLE, M., FRUCHART, J.C., DEEB, S., VIDAL-PUIG, A., FLIER, J., BRIGGS, M.R., STAELS, B., VIDAL, H. & AUWERX, J. (1997). The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem., 272, 18779-18789.
8. FINEGOOD, D.T., MCARTHUR, M.D., KOJWANG, D., THOMAS, M.J., TOPP, B.G., LEONARD, T. & BUCKINGHAM, R.E. (2001). β-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes, 50, 1021-1029.
9. GIACCARI, A., MORVIDUCCI, L., ZORRETTA, D., SBRACCIA, P., LEONETTI, F., CAIOLA, S., BUONGIORNO, A., BONADONNA, R.C. & TAMBURRANO, G. (1995). In vivo effects of glucosamine on insulin secretion and insulin sensitivity in the rat: possible relevance to the maladaptive responses to chronic hyperglycaemia. Diabetologia, 38, 518-524.
10. GRIFFEN, S.C., WANG, J. & GERMAN, M.S. (2001). A genetic defect in β-cell gene expression segregrates independently from the fa locus in the ZDF rat. Diabetes, 50, 63-68.
11. GUERRE-MILLO, M., GERVOIS, P., RASPE, E., MADSEN, L., POULAIN, P., DERUDAS, B., HERBERT, J.M., WINEGAR, D.A., WILLSON, T.M., FRUCHART, J.C., BERGE, R.K. & STAELS, B. (2000). Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem., 275, 16638-16642.
12. HARMON, J.S., GLEASON, C.E., TANAKA, Y., POITOUT, V. & ROBERTSON, R.P. (2001). Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes, 50, 2481-2486.
13. HAUBENWALLNER, S., ESSENBURG, A.D., BARNETT, B.C., PAPE, M.E., DEMATTOS, R.B., KRAUSSE, B.R., MINTON, L.L., AUERBACH, B.J., NEWTON, R.S., LEFF, T. & BISGAIERL, C.L. (1995). Hypolipidemic activity of select fibrates correlates to changes in hepatic lipolipoprotein C-III expression: a potential physiologic basis for their mode of action. J. Lipid Res., 36, 2541-2551.
14. KAWAMORI, R., MATSUHISA, M., KINOSHITA, J., MOCHIZUTI, K., NIWA, M., ARISAKA, T., IKEDA, M., KUBOTA, M., WADA, M., KANDA, T., IKEBUCHI, M., TOHDO, R. & YAMASAKI, Y. (1998). Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp OGL Study Group. Diabetes Res. Clin. Pract., 41, 35-43.
15. LARSEN, P.J., JENSEN, P.B., SØRENSEN, R.V., LARSEN, L.K., VRANG, N., WULFF, E.M. & WASSERMANN, K. (2003). Differential influences of peroxisome proliferator-activated receptor γ and -α on food intake and energy homeostasis. Diabetes, 52, 2249-2259.
16. LJUNG, B., BAMBERG, K., DAHLLÖF, B., KJELLSTEDT, A., OAKES, N.D., OSTLING, J., SVENSSON, L. & CAMEJO, G. (2002). AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res., 43, 1855-1863.
17. LOHRAY, B.B., LOHRAY, V.B., BAJJI, A.C., KALCHAR, S., POONDRA, R.R., PADAKANTI, S., CHAKRABARTI, R., VIKRAMADITHYAN, R.K., MISRA, P., JULURI, S., MAMIDI, N.V. & RAJAGOPALAN, R. (2001). (-)3-(4-(2-(Phenoxasin-10-yl)ethoxy) phenyl)-2-ethoxypropanoic acid ((-)DRF 2725): a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem., 44, 2675-2678.
18. MATSUI, H., OKUMURA, K., KAWAKAMI, K., HIBINO, M., TOKI, Y. & ITO, T. (1997). Improved insulin sensitivity by bezafibrate in rats: relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes, 46, 348-353.
19. MATTHEWS, D.R., HOSKER, J.P., RUDENSKI, A.S., NAYLOR, B.A., TREACHER, D.F. & TURNER, R.C. (1985). Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia, 28, 412-419.
20. MOORE, G.B., CHAPMAN, H., HOLDER, J.C., LISTER, C.A., PIERCY, V., SMITH, S.A. & CLAPHAM, J.C. (2001). Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem. Biophys. Res. Commun., 286, 735-741.
21. MURAKAMI, K., TOBE, K., IDE, T., MOCHIZUKI, T., OHASHI, M., AKANUMA, Y., YAZAKI, Y. & KADOWAKI, T. (1998). A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes, 47, 1841-1847.
22. MURAKAMI, K., TSUNODA, M., IDE, T., OHASHI, M. & MOCHIZUKI, T. (1999). Amelioration by KRP-297, a new thiazolidinedione, of impaired glucose uptake in skeletal muscle from obese insulin-resistant animals. Metabolism, 48, 1450-1454.
23. PETERSON, R.G. (1994). The Zucker diabetic fatty (ZDF) rat. In: Lessons from Animal Diabetes. ed. Shafrir, E. pp. 225-230. London: Smith-Gordon.
24. PICKAVANCE, L., WIDDOWSON, P.S., FOSTER, J.R., WILLIAMS, G. & WILDING, J.P. (2003). Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker diabetic fatty rat. Int. J. Exp. Path., 84, 83-89.
25. REAVEN, G.M. (1988). Role of insulin resistance in human disease. Diabetes, 37, 1595-1607.
26. SAAD, M.F., GRECO, S., OSEI, K., LEWIN, A.J., EDWARDS, C., NUNEZ, M. & REINHARDT, R.R. (2004). Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care, 27, 1324-1329.
27. SAKAMOTO, J., KIMURA, H., MORIYAMA, S., ODAKA, H., MOMOSE, Y., SUGIYAMA, Y. & SAWADA, H. (2000). Activation of human peroxisome proliferator- activated receptor (PPAR) subtypes by pioglitazone. Biochem. Res. Commun., 278, 704-711.
28. SAUERBERG, P., PETTERSSON, I., JEPPESEN, L., BURY, P.S., MOGENSEN, J.P., WASSERMANN, K., BRAND, C.L., STURIS, J., WOLDIKE, H.F., FLECKNER, J., ANDERSEN, A.S., MORTENSEN, S.B., SVENSSON, L.A., RASMUSSEN, H.B., LEHMANN, S.V., POLIVKA, Z., SINDELAR, K., PANAJOTOVA, V., YNDDAL, L. & WULFF, E.M. (2002). Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity. J. Med. Chem., 45, 789-804.
29. SHIMABUKURO, M., ZHOU, Y.-T., LEE, Y. & UNGER, R.H. (1998). Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem., 273, 3547-3550.
30. SKRUMSAGER, B.K., NIELSEN, K.K., MULLER, M., PABST, G., DRAKE, P.G. & EDSBERG, B. (2003). Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J. Clin. Pharmacol., 43, 1244-1256.
31. SPIEGELMAN, B.M. (1998). PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes, 47, 507-514.
32. STURIS, J., GOTFREDSEN, C.F., RØMER, J., TORNEHAVE, D., GALSGAARD, E.D., VØLUND, A., WASSERMANN, K., KNUDSEN, L.B. & BRAND, C.L. (2002). Synergistic effects of the dual-acting PPARα and γ agonist ragaglitazar and the long-acting GLP-1 derivative NN2211 on glycemic control in diabetic ZDF rats. Diabetes, 51 (Suppl. 2), A34.
33. UNGER, R.H. (1995). Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications. Diabetes, 44, 863-870.
34. UNGER, R.H. (1997). How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol. Metab., 7, 276-282.
35. VETTOR, R., PAGANO, C., GRANZOTTO, M., ENGLARO, P., ANGELI, P., BLUM, W.F., FEDERSPIL, G., ROHNER-JEANRENAUD, F. & JEANRENAUD, B. (1998). Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats. Diabetologia, 41, 1361-1367.
36. WILDING, J.P., GILBEY, S.G., MANNAN, M., ASLAM, N., GHATEI, M.A. & BLOOM, S.R. (1992). Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. J. Endocrinol., 132, 299-304.
37. WILLSON, T.M., BROWN, P.J., STERNBACH, D.D. & HENKE, B.R. (2000). The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 43, 527-550.
38. YAJIMA, K., HIROSE, H., FUJITA, H., SETO, Y., FUJITA, H., UKEDA, K., MIYASHITA, K., KAWAI, T., YAMAMOTO, Y., OGAWA, T., YAMADA, T. & SARUTA, T. (2003). Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice. Am. J. Physiol. Endocrinol. Metab., 284, E966-E971.
39. YE, J.-M., DOYLE, P.J., IGLESIAS, M.A., WATSON, D.G., COONEY, G.J. & KRAEGEN, E.W. (2001). Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Comparison with PPAR-γ activation. Diabetes, 50, 411-417.
40. YE, J.-M., IGLESIAS, M.A., WATSON, D.G., ELLIS, B., WOOD, L., JENSEN, P.B., SØRENSEN, R.V., LARSEN, P.J., COONEY, G.J., WASSERMANN, K. & KRAEGEN, E.W. (2003). PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. J. Physiol. Endocrinol. Metab., 284, E531-E540.
41. ZHOU, Y.T., SHIMABUKURO, M., WANG, M.Y., LEE, Y., HIGA, M., MILBURN, J.L., NEWGARD, C.B. & UNGER, R.H. (1998). Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells. Proc. Natl. Acad. Sci. U.S.A., 95, 8898-8903.